myfortic
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Gastrointestinal Lesions
Conditions
Gastrointestinal Lesions, Signs and Symptoms, Digestive
Trial Timeline
Apr 1, 2009 → May 1, 2011
NCT ID
NCT00652834About myfortic
myfortic is a approved stage product being developed by Novartis for Gastrointestinal Lesions. The current trial status is completed. This product is registered under clinical trial identifier NCT00652834. Target conditions include Gastrointestinal Lesions, Signs and Symptoms, Digestive.
What happened to similar drugs?
7 of 20 similar drugs in Gastrointestinal Lesions were approved
Approved (7) Terminated (4) Active (9)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04645589 | Pre-clinical | Completed |
| NCT00652834 | Approved | Completed |
| NCT01261169 | Pre-clinical | UNKNOWN |
| NCT00468936 | Phase 3 | UNKNOWN |
| NCT00336895 | Pre-clinical | Completed |
| NCT00676221 | Approved | UNKNOWN |
| NCT00298883 | Phase 1 | Completed |
| NCT00167492 | Approved | Withdrawn |
| NCT00101738 | Phase 3 | Completed |
Competing Products
20 competing products in Gastrointestinal Lesions